Home › Funds › Trails Edge Capital Partners, LP › FDMT
Trails Edge Capital Partners, LP position in FDMT
4D MOLECULAR THERAPEUTICS IN · Health Care
Trails Edge Capital Partners, LP reported holding 2,227,917 shares of FDMT (4D MOLECULAR THERAPEUTICS IN) in its Q2 2026 13F filing — a position valued at US$29.6M, representing 4.70% of its reported portfolio and ranking #5 among its reported holdings. Trails Edge Capital Partners, LP has disclosed FDMT holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Trails Edge Capital Partners, LP's FDMT position evolved
Trails Edge Capital Partners, LP first disclosed a stake in FDMT in Q1 2026 at 1,302,917 shares (US$12.1M). The position peaked in Q2 2026 at 2,227,917 shares, worth US$29.6M. Across 2 filings, Trails Edge Capital Partners, LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 2,227,917 shares valued at US$29.6M — an increase of 925,000 shares quarter over quarter.. Notable position changes include a 71% increase in Q2 2026 (shares rose 8% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 1.30M | $12.13M | New |
| Q2 2026 | 2.23M | $29.63M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About FDMT and 13F data
FDMT (4D MOLECULAR THERAPEUTICS IN) is a Health Care company. 35 other funds we track also report a position in FDMT — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$67.2M), Novo Holdings A/S (US$43.2M), BVF INC/IL (US$38.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding FDMT
- RA CAPITAL MANAGEMENT, L.P. 5.05M sh · $67.16M · Q2 2026
- Novo Holdings A/S 3.25M sh · $43.21M · Q2 2026
- BVF INC/IL 2.88M sh · $38.29M · Q2 2026
- ARMISTICE CAPITAL, LLC 2.00M sh · $26.60M · Q2 2026
- Evergreen Quality Fund GP, Ltd. 951.47K sh · $12.65M · Q2 2026
- Parkman Healthcare Partners LLC 948.18K sh · $12.61M · Q2 2026
- DIADEMA PARTNERS LP 571.11K sh · $7.60M · Q2 2026
- ACUTA CAPITAL PARTNERS, LLC 507.80K sh · $6.75M · Q2 2026
- Catalio Capital Management, LP 471.25K sh · $6.27M · Q2 2026
- Opaleye Management Inc. 334.44K sh · $4.45M · Q2 2026
More on Trails Edge Capital Partners, LP
FAQ
How long has Trails Edge Capital Partners, LP held FDMT?
Trails Edge Capital Partners, LP has disclosed FDMT holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Trails Edge Capital Partners, LP's current position in FDMT?
As of Q2 2026, Trails Edge Capital Partners, LP holds 2.23M shares of FDMT (4D MOLECULAR THERAPEUTICS IN), valued at $29.63M, representing 4.70% of its reported portfolio and ranking #5.
Has Trails Edge Capital Partners, LP been buying or selling FDMT?
In the latest 13F filing (Q2 2026), Trails Edge Capital Partners, LP increased its position in FDMT. The position peaked in Q2 2026 at 2.23M shares.
Which other funds hold FDMT?
Other major institutional holders of FDMT include RA CAPITAL MANAGEMENT, L.P., Novo Holdings A/S, BVF INC/IL, among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.